Neurodegenerative Diseases: Integrative Pppm Approach as the Medicine of the Future

ISBN-13: 9789400792951 / Angielski / Miękka / 2015 / 398 str.

Silvia Mandel

Opis

This book will compile a collection of chapters dedicated to varied aspects of PPPM in neuropsychiatric and neurodegenerative diseases. Among the topics to be covered are:
Recent advances in ALS research
News about Clinical aspects and advanced therapy approaches in personalized treatment of ALS Schizophrenia: New treatments and clinical aspects
Predictive, Preventive and Personalised Medicine in aging macular degeneration
Advances in Multiple Sclerosis Pharmacogenetics, Tailoring Treatment Efficacy, Safety and Regimen Selection
Multiple sclerosis related biomarkers: perspectives for clinical application
Preventive clinical trials in brain aging: new trends & the need of guidelines
MCI_ clinical guidelines in early diagnosis of dementia
Alzheimer's disease: diagnostics, prognostics and the road to prevention
Biomarkers for early diagnosis of Parkinson's and Alzheimer's diseases
Synucleinopathies, tauopathies, TDP-43 proteinopathies and amyloidosis PSP, MSA and other parkinsonisms

Recenzje

From the reviews:

"This book provides an overview of up-to-date literature on existing and potential future predictive, preventive, and personalized therapeutic approaches to neurodegenerative diseases. It is a useful resource for clinicians and researchers interested in the current status of research findings and their potential future applications in this field." (Nilufer Ertekin-Taner, Doody's Book Reviews, October, 2013)

Spis treści

Part I

1. What is this book series about? Foreword of Book Series Editor; O. Golubnitschaja

2. Preface; S. Mandel

3.     Introductory chapter; S. Mandel and O. Golubnitschaja

Part II

4. Individual predispositions in healthy vasospastic individuals: Patient profiling for targeted prevention of “down-stream” pathologies as cost-effective personalised medicine; K. Yeghiazaryan, J. Flammer, O. Golubnitschaja

5. Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders; S. Fulda and M. Manconi

6. New animal models of progressive neurodegeneration:  tools for developing predictive diagnostics and identifying presymptomatic therapeutic targets; A. L. Marriott, D. A. Gill, C. A. Shaw, R. A. Tasker

7. Tau pathology: A selected view on the current status; I. Gozes

Part III

8. The Use of Biomarkers for Prediction and Prevention of Alzheimer's and Parkinson's Diseases; S. A. Mandel & A. D. Korczyn

9. Making clinical trials of Alzheimer’s disease delay-of-onset a reality by use of a prognostic genetic biomarker; Iris Grossman

10. An update on CSF biomarkers of Parkinson’s disease; Peter LeWitt, B Russell Huber, Jing Zhang

Part IV

11. Glaucomatous optic neuropathy: Risk assessment and potential targets for effective prevention and treatments tailored to the patient; O. Golubnitschaja, K. Yeghiazaryan, J. Flammer

Part V

12. Toward a personalized approach in amyotrophic lateral sclerosis: new developments in diagnosis, genetics, pathogenesis and therapies; B. Nefussy & V. E. Drory

13. Recent advances in ALS research: perspectives for personalized clinical application; C. Benkler, D. Offen, E. Melamed, T. Amit, S. Mandel, M. B.H. Youdim, O. Weinreb

Part VI

14. Exercise in Multiple Sclerosis – an Integral Component of Disease Management; A. Döring, C. F. Pfueller, F. Pau, J. Dörr

15. Bridging the Informatics Gap between Bench and Bedside: Implications to Neurodegenerative Diseases; A. Shabo (Shvo) & M. Scarpa

Part VII

16. Personalized Medicine In Rare Paediatric Neurometabolic Diseases; R. Tomanin, C. M. Bellettato, F. D’Avanzo, A. Zanetti, A. Ceci, D. Begley, M. Scarpa

Blurb

The economic burden of dementia was estimated as being US$ 604 billion in 2010. Now it is time for new guidelines in handling of neurodegenerative disorders. Optimistic versus Pessimistic Prognosis depends much on diagnostic and treatment approaches which healthcare will preferably adopt in the near future. Current dramatic situation can be significantly improved by the implementation of appropriate early diagnostic, targeted preventive measures and therapies tailored to the person advancing healthcare and enhancing the patient life quality. Neurodegenerative Diseases are pathologies of multi-factorial nature involving interplay of epi/genetic and environmental risk factors. Insights into molecular pathomechanisms will enable to create the most effective neuro-protective strategies and individualised treatment before manifest pathology. Utilization of the advanced integrative medical approach could enable a significant portion of population to reach the 100-year age limit remaining vibrant in excellent physical and mental health as actively contributing members of the society. The crucial role of the integrative approach by PPPM has been acknowledged as priorities by World Health Organization, United Nations and the European Union among others. Extensive efforts of international consortia are essential in the field to consolidate the accumulated expertise and to create population screening, robust diagnostic approaches, effective prevention in groups at high risk and targeted treatments.

This book volume "Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future" is intended to serve as a reference source for basic researchers and healthcare industry involved in the field of neurosciences with a special emphasis on mental health promotion and innovations intended to delay or even prevent neurodegenerative diseases.